Finally, we demonstrate the potential of rationally designing targeted combination therapy regimens for CRC
If you can, get bloodwork done (blood sugar and cholesterol levels)
Phase 3 TRIUMPH program ongoing Dosing / Once-weekly subcutaneous injection, studied at 1 mg to 12 mg Efficacy / 24.2% mean weight loss at 48 weeks with 12 mg dose in Phase 2 (N=338) Common side effects / Nausea, diarrhea, vomiting, constipation (mostly mild-to-moderate) Young-adult concern / Bone mineral density still accruing until age 25-30 Fertility note / No human fertility data
Contaminated or degraded diluents introduce variables that could cause reactions
However, because much of the data comes from small human trials and preclinical research, the full spectrum of risks isnt completely known
Stroke-related outcomes: GLP-1 RAs were associated with a reduced risk of stroke, including non-fatal and fatal subtypes